Optimizing heart failure therapy with enhanced medical management: focus on heart rate management
DOI:
https://doi.org/10.18203/issn.2454-2156.IntJSciRep20242696Keywords:
HF, Heart rate management, Guideline-directed medical therapy, BBs, IvabradineAbstract
Heart failure (HF) is a significant global health issue, affecting over 60 million people worldwide, with its prevalence expected to rise due to aging populations and the increasing incidence of comorbidities like hypertension and diabetes. Despite therapeutic advances, including quadruple therapy with renin-angiotensin-system inhibitors, beta blockers (BB), mineralocorticoid receptor antagonists, and sodium-glucose cotransporter 2 inhibitors, HF remains a condition with a poor prognosis, particularly for those with reduced ejection fraction (HFrEF), who are predominantly found in low- and middle-income countries like India. Elevated resting heart rate (HR) is a critical prognostic factor in HF, correlating strongly with cardiovascular mortality and morbidity. For every five-beat increase in HR, there is a 16% rise in cardiovascular mortality and HF hospitalization, emphasizing the need for effective HR management. However, challenges persist in optimizing HF treatment, such as the underutilization of BBs, despite their proven efficacy in reducing mortality. In India, the "double burden" of age-related and contemporary diseases complicates HF management further. Addressing unmet needs in HF care requires optimizing therapeutic strategies and improving treatment adherence, particularly in the context of HR control. Studies indicate that tailored approaches, including the use of BBs and ivabradine, could reduce HR and improve clinical outcomes. The ongoing challenges in accessing guideline-directed therapy and ensuring adherence highlight the need for comprehensive strategies to enhance patient outcomes, while personalized treatments and further research remain essential in navigating the complex landscape of HF management.
Metrics
References
Harikrishnan S, Koshy L, Ganapathi S, Jeemon P, Kumar RK, Roy A, et al. Charting a roadmap for HF research in India: Insights from a qualitative survey. Indian J Med Res. 2023;158(2):182-9.
Sawhney JP, Jain P, Kantanavar K. Management of HF patients with systolic dysfunction in a real-world setting-a physician-based survey. Int J Adv Med. 2023;10:527-37.
Lavalle C, Di Lullo L, Jabbour JP, Palombi M, Trivigno S, Mariani MV, et al. New Challenges in HF with Reduced Ejection Fraction: Managing Worsening Events. J Clin Med. 2023;12(22):6956.
Bozkurt B. How to Initiate and Uptitrate GDMT in HF: Practical Stepwise Approach to Optimization of GDMT. JACC Heart Fail. 2022;10(12):992-5.
Khan ZM, Briere JB, Olewinska E, Khrouf F, Nikodem M. Ivabradine in patients with HF: a systematic literature review. J Mark Access Health Policy. 2023;11(1):2262073.
Böhm M, Reil JC. HR: surrogate or target in the management of HF? Heart. 2013;99(2):72-5.
Fox K, Ford I, Steg PG, Tendera M, Robertson M, Ferrari R, et al. HR as a prognostic risk factor in patients with coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a subgroup analysis of a randomised controlled trial. Lancet. 2008;372(9641):817-21.
Custodis F, Reil JC, Laufs U, Böhm M. HR: a global target for cardiovascular disease and therapy along the cardiovascular disease continuum. J Cardiol. 2013;62(3):183-7.
Bui AL, Grau-Sepulveda MV, Hernandez AF, Peterson ED, Yancy CW, Bhatt DL, et al. Admission HR and in-hospital outcomes in patients hospitalized for HF in sinus rhythm and in atrial fibrillation. Am Heart J. 2013;165(4):567-574.
Laskey WK, Alomari I, Cox M, Schulte PJ, Zhao X, Hernandez AF, et al. AHA Get with The Guidelines®‐HF Program. HR at hospital discharge in patients with HF is associated with mortality and rehospitalization. J Am Heart Assoc. 2015;4(4):e001626.
Takada T, Sakata Y, Miyata S, Takahashi J, Nochioka K, Miura M, et al. CHART-2 Investigators. Impact of elevated HR on clinical outcomes in patients with HF with reduced and preserved ejection fraction: a report from the CHART-2 Study. Eur J Heart Fail. 2014;16(3):309-16.
Oomman A, Bansal M. Adding ivabradine to beta-blockers in chronic HF: Do not rest without lowering the resting HR sufficiently. Indian Heart J. 2018;70(2):201-3.
Pereira-Barretto AC. Addressing Major Unmet Needs in Patients with Systolic HF: The Role of Ivabradine. Am J Cardiovasc Drugs. 2016;16(2):93-101.
Guha S, Harikrishnan S, Ray S, Sethi R, Ramakrishnan S, Banerjee S, et al. CSI position statement on management of HF in India. Indian Heart J. 2018;70(1):S1-72.
Chaturvedi V, Parakh N, Seth S, Bhargava B, Ramakrishnan S, Roy A, et al. HF in India: The INDUS (INDia Ukieri Study) study. J Pract Cardiovasc Sci. 2016;2:28-35.
Kim AH, Jang JE, Han J. Current status on the therapeutic strategies for HF and diabetic cardiomyopathy. Biomed Pharmacother. 2022;145:112463.
Nair T. 75th Annual Conference of Cardiology society of India. Indian Heart J. 2023;75(1):S29-123.